These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 9368550)

  • 41. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.
    Haley EC; Levy DE; Brott TG; Sheppard GL; Wong MC; Kongable GL; Torner JC; Marler JR
    Stroke; 1992 May; 23(5):641-5. PubMed ID: 1579959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.
    Grotta J;
    Cerebrovasc Dis; 2001; 12(3):258-63. PubMed ID: 11641593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study.
    Saqqur M; Molina CA; Salam A; Siddiqui M; Ribo M; Uchino K; Calleja S; Garami Z; Khan K; Akhtar N; O'Rourke F; Shuaib A; Demchuk AM; Alexandrov AV;
    Stroke; 2007 Jan; 38(1):69-74. PubMed ID: 17138949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study.
    Larrue V; von Kummer R; del Zoppo G; Bluhmki E
    Stroke; 1997 May; 28(5):957-60. PubMed ID: 9158632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
    Robinson TG; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Demchuk AM; Donnan GA; Kim JS; Lavados PM; Lee TH; Lindley RI; Martins SCO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Nguyen TH; Wang JG; Woodward M; Chalmers J; Anderson CS;
    Stroke; 2017 Jul; 48(7):1877-1883. PubMed ID: 28619989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke.
    Ohta T; Okada K; Fukuda M; Masahira N; Matsuoka T; Tsuno T; Takemura M
    J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):1844-1851. PubMed ID: 29555402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SYNTHESIS expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke.
    Ciccone A; Valvassori L; Nichelatti M;
    Int J Stroke; 2011 Jun; 6(3):259-65. PubMed ID: 21557814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group.
    Jaillard A; Cornu C; Durieux A; Moulin T; Boutitie F; Lees KR; Hommel M
    Stroke; 1999 Jul; 30(7):1326-32. PubMed ID: 10390303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage.
    Vandelli L; Marietta M; Gambini M; Cavazzuti M; Trenti T; Cenci MA; Casoni F; Bigliardi G; Pentore R; Nichelli P; Zini A
    J Stroke Cerebrovasc Dis; 2015 Feb; 24(2):394-400. PubMed ID: 25497721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TURN Score Predicts 24-Hour Cerebral Edema After IV Thrombolysis.
    Asuzu D; Nyström K; Sreekrishnan A; Schindler J; Wira C; Greer D; Halliday J; Kimberly WT; Sheth KN
    Neurocrit Care; 2016 Jun; 24(3):381-8. PubMed ID: 26341364
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.
    Clark WM; Albers GW; Madden KP; Hamilton S
    Stroke; 2000 Apr; 31(4):811-6. PubMed ID: 10753980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
    Rhoney DH; Coplin WM; Lin Y; Frankel M; Lyden PD; Levine SR
    J Stroke Cerebrovasc Dis; 2010 Jan; 19(1):40-8. PubMed ID: 20123226
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials.
    Rao NM; Levine SR; Gornbein JA; Saver JL
    Stroke; 2014 Sep; 45(9):2728-33. PubMed ID: 25096731
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria.
    Hemmen TM; Rapp KS; Emond JA; Raman R; Lyden PD
    J Stroke Cerebrovasc Dis; 2010; 19(4):290-3. PubMed ID: 20471855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Remote Intracerebral Hemorrhage After Intravenous Thrombolysis: Results From a Multicenter Study.
    Prats-Sánchez L; Camps-Renom P; Sotoca-Fernández J; Delgado-Mederos R; Martínez-Domeño A; Marín R; Almendrote M; Dorado L; Gomis M; Codas J; Llull L; Gómez González A; Roquer J; Purroy F; Gómez-Choco M; Cánovas D; Cocho D; Garces M; Abilleira S; Martí-Fàbregas J;
    Stroke; 2016 Aug; 47(8):2003-9. PubMed ID: 27406103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group.
    Tanne D; Bates VE; Verro P; Kasner SE; Binder JR; Patel SC; Mansbach HH; Daley S; Schultz LR; Karanjia PN; Scott P; Dayno JM; Vereczkey-Porter K; Benesch C; Book D; Coplin WM; Dulli D; Levine SR
    Neurology; 1999 Jul; 53(2):424-7. PubMed ID: 10430444
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ginsenoside Represses Symptomatic Intracerebral Hemorrhage after Recombinant Tissue Plasminogen Activator Therapy by Promoting Transforming Growth Factor-β1.
    Chen J; Bai Q; Zhao Z; Sui H; Xie X
    J Stroke Cerebrovasc Dis; 2016 Mar; 25(3):549-55. PubMed ID: 26683593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
    Diedler J; Ahmed N; Sykora M; Uyttenboogaart M; Overgaard K; Luijckx GJ; Soinne L; Ford GA; Lees KR; Wahlgren N; Ringleb P
    Stroke; 2010 Feb; 41(2):288-94. PubMed ID: 20056933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke.
    Brown DL; Barsan WG; Lisabeth LD; Gallery ME; Morgenstern LB
    Ann Emerg Med; 2005 Jul; 46(1):56-60. PubMed ID: 15988427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcome of patients with negative CT angiography results for arterial occlusion treated with intravenous thrombolysis.
    Mikulik R; Goldemund D; Reif M; Aulicky P; Krupa P
    Stroke; 2009 Mar; 40(3):868-72. PubMed ID: 19131650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.